HCC
PBYI icon

Hirtle Callaghan & Co’s Puma Biotechnology PBYI Stock Holding History

Hirtle Callaghan & Co’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-500
Closed -$33K – 611
2014
Q2 		$33K Buy
+500
New +$35.6K ﹤0.01% 410

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Hirtle Callaghan & Co's PBYI Position: Q3 2014 in Review

Hirtle Callaghan & Co sold out of Puma Biotechnology (PBYI) in Q3 2014, closing a stake of 500 shares — an estimated $33K sold.

Hirtle Callaghan & Co first reported a position in PBYI in Q2 2014 and held it in 1 quarter. The position peaked at $33K in Q2 2014. 184 funds tracked by Wall St. Rank hold PBYI as of Q3 2014.

  • Hirtle Callaghan & Co reported no remaining Puma Biotechnology position as of Q3 2014 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 500 Puma Biotechnology shares in Q3 2014, an estimated $33K.
  • Hirtle Callaghan & Co first reported a position in Puma Biotechnology in Q2 2014 and held it in 1 quarter.
  • Hirtle Callaghan & Co's Puma Biotechnology position peaked at $33K in Q2 2014.
  • 184 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2014.

Based on Hirtle Callaghan & Co's 13F filing for Q3 2014, filed 29 Oct 2014.